In addition, the expression of SEC61A1 serves as an indicator for poor OS in non-FLT3 mutant AML patients (TCGA-AML, P = 0.028) (Figure 2a), with SEC61A1 demonstrating notably dismal survival outcomes in the intermediate to high-risk groups (Figure 2b–d). This evidence concerns the gene FLT3 and acute myeloid leukemia.